On Feb. 18, 2021, Novavax and announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to provide 1.1 billion cumulative doses of NVX-CoV2373, Novavaxﾒ recombinant protein-based COVID-19 vaccine candidate, for the COVAX Facility.

The vaccine doses were manufactured and distributed globally by Novavax and Serum Institute of India (SII). NVX-CoV2373 was being studied in two ongoing pivotal Phase 3 clinical trials: in the U.S. and Mexico, as well as in the U.K., for the prevention of COVID-19. Novavax has previously reported positive interim efficacy results from its U.K. trial.